Efficacy and safety of fondaparinux versus enoxaparin in patients undergoing percutaneous coronary intervention treated with the glycoprotein IIb

IMR OpenIR

	Efficacy and safety of fondaparinux versus enoxaparin in patients undergoing percutaneous coronary intervention treated with the glycoprotein IIb
其他题名	Efficacy and safety of fondaparinux versus enoxaparin in patients undergoing percutaneous coronary intervention treated with the glycoprotein IIb
	Xin Zhao 1; Xiao-Xu Yang 2; Su-Zhen Ji 1; Xiao-Zeng Wang 1; Li Wang 1; Chong-Huai Gu 1; Li-Li Ren 1; Ya-Ling Han 1
	2016-01-01
发表期刊	Military Medical Research
ISSN	2054-9369
卷号	3 期号:1
摘要	In worldwide, the mortality rate of acute myocardial infarction (AMI) raises year by year. Although the applications of percutaneous coronary intervention (PCI) and anticoagulants effectively reduce the mortality of patients with acute coronary syndrome (ACS), but also increase the incidence of bleeding. Therefore, drugs with stable anticoagulant effects are urgently required.
其他摘要	Background In worldwide, the mortality rate of acute myocardial infarction (AMI) raises year by year. Although the applications of percutaneous coronary intervention (PCI) and anticoagulants effectively reduce the mortality of patients with acute coronary syndrome (ACS), but also increase the incidence of bleeding. Therefore, drugs with stable anticoagulant effects are urgently required. Methods We enrolled 894 patients with acute coronary syndrome who underwent percutaneous coronary intervention in Shenyang Northern Hospital from February 2010 to May 2012; 430 patients were included in the fondaparinux group (2.5mg Results One-year data were available for 422 patients in the fondaparinux group and for 453 in the enoxaparin group. The incidence of a major adverse cerebrovascular or cardiovascular event (10.9% vs 12.6%, P ?=?0.433) and cardiac mortality (0.5% vs 1.5%, P ?=?0.116) were generally lower in the fondaparinux group than in the enoxaparin group, although the differences were not significant. Compared with the enoxaparin group, the fondaparinux group had a significantly decreased rate of bleeding at 30days (0.9% vs 2.8%) and 1year (2.4% vs 5.4%). In addition, the rate of major bleeding events was lower in the fondaparinux group, but this difference was not significant (0.2% vs 0.9%, 0.2% vs 1.1%). Conclusions In tirofiban-treated patients with acute coronary syndrome undergoing percutaneous coronary intervention, fondaparinux presented similar efficacy for ischemia events as enoxaparin. However, fondaparinux significantly decreased the incidence of bleeding, thus providing safer anticoagulation therapy.
语种	英语
文献类型	期刊论文
条目标识符	http://ir.imr.ac.cn/handle/321006/159371
专题	中国科学院金属研究所
作者单位	1.Institute of Metal Research, Chinese Academy of Sciences 2.沈阳医学院
推荐引用方式 GB/T 7714	Xin Zhao,Xiao-Xu Yang,Su-Zhen Ji,et al. Efficacy and safety of fondaparinux versus enoxaparin in patients undergoing percutaneous coronary intervention treated with the glycoprotein IIb[J]. Military Medical Research,2016,3(1).
APA	Xin Zhao.,Xiao-Xu Yang.,Su-Zhen Ji.,Xiao-Zeng Wang.,Li Wang.,...&Ya-Ling Han.(2016).Efficacy and safety of fondaparinux versus enoxaparin in patients undergoing percutaneous coronary intervention treated with the glycoprotein IIb.Military Medical Research,3(1).
MLA	Xin Zhao,et al."Efficacy and safety of fondaparinux versus enoxaparin in patients undergoing percutaneous coronary intervention treated with the glycoprotein IIb".Military Medical Research 3.1(2016).